Safety of targeting ROR1 for cancer immunotherapy with chimeric antigen receptor-modified T cells in a primate model
Crossref DOI link: https://doi.org/10.1186/2051-1426-2-S3-P3
Published Online: 2014-11-06
Published Print: 2014-12
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Berger, S Carolina
Sommermeyer, Daniel
Hudecek, Michael
Berger, Michael
Balakrishnan, Ashwini
Paskiewicz, Paulina
Kosasih, Paula
Rader, Christoph
Riddell, Stanley
Article History
First Online: 6 November 2014